Literature DB >> 865153

Platelet monoamine oxidase, plasma benzylamine oxidase and liver mixed function oxidase in cirrhotic patients.

F Buffoni, G Ignesti, R Pirision, C Cortesini.   

Abstract

Because it has been suggested that an accumulation of false neurochemical transmitters plays a part in the cardiovascular and neurological complications of cirrhosis it appeared worthwhile to study the level of monoamine oxidase in the liver and platelets of cirrhotic patients. In fact a decrease of such activities might explain the increase of false neurotransmitters observed in cirrhotic patients. Other enzyme were also tested: the plasma benzylamine oxidase activity and the liver mixed function oxidases. 13 cases of severe cirrhosis (B, C according to Child classification) and 10 cases of less severe cirrhosis (A according to Child classification) were studied in comparison to patients affected by cholelithiasis. A defect in the level of monoamine oxidase activity of platelets and liver was observed in some cirrhotic patients together with a decrease of the level of the liver mixed function oxidases.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 865153

Source DB:  PubMed          Journal:  Med Biol        ISSN: 0302-2137


  4 in total

1.  The effect of age on the activity and molecular properties of human brain monoamine oxidase.

Authors:  C J Fowler; A Wiberg; L Oreland; J Marcusson; B Winblad
Journal:  J Neural Transm       Date:  1980       Impact factor: 3.575

2.  Titration of human brain type-B monoamine oxidase.

Authors:  C J Fowler; A Wiberg; L Oreland; B Winblad
Journal:  Neurochem Res       Date:  1980-07       Impact factor: 3.996

3.  Biochemical aspects and functional role of the copper-containing amine oxidases.

Authors:  F Buffoni; G Ignesti
Journal:  Inflammopharmacology       Date:  2003       Impact factor: 4.473

4.  Titration of human brain monoamine oxidase -A and -B by clorgyline and L-deprenil.

Authors:  C J Fowler; L Oreland; J Marcusson; B Winblad
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1980-04       Impact factor: 3.000

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.